ATE175212T1 - Cai-resistenzproteine kodierende dna, und ihre verwendung - Google Patents

Cai-resistenzproteine kodierende dna, und ihre verwendung

Info

Publication number
ATE175212T1
ATE175212T1 AT95914156T AT95914156T ATE175212T1 AT E175212 T1 ATE175212 T1 AT E175212T1 AT 95914156 T AT95914156 T AT 95914156T AT 95914156 T AT95914156 T AT 95914156T AT E175212 T1 ATE175212 T1 AT E175212T1
Authority
AT
Austria
Prior art keywords
dna encoding
cai
resistance proteins
cai resistance
functionally equivalent
Prior art date
Application number
AT95914156T
Other languages
English (en)
Inventor
Elise C Kohn
Lance A Liotta
Young Sook Kim
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Application granted granted Critical
Publication of ATE175212T1 publication Critical patent/ATE175212T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT95914156T 1994-03-14 1995-03-14 Cai-resistenzproteine kodierende dna, und ihre verwendung ATE175212T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/212,190 US5652223A (en) 1994-03-14 1994-03-14 DNA encoding CAI resistance proteins and uses thereof

Publications (1)

Publication Number Publication Date
ATE175212T1 true ATE175212T1 (de) 1999-01-15

Family

ID=22789940

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95914156T ATE175212T1 (de) 1994-03-14 1995-03-14 Cai-resistenzproteine kodierende dna, und ihre verwendung

Country Status (11)

Country Link
US (2) US5652223A (de)
EP (1) EP0750637B1 (de)
JP (1) JPH09511236A (de)
AT (1) ATE175212T1 (de)
AU (1) AU684930B2 (de)
CA (1) CA2185341A1 (de)
DE (1) DE69507017T2 (de)
DK (1) DK0750637T3 (de)
ES (1) ES2128048T3 (de)
GR (1) GR3029811T3 (de)
WO (1) WO1995025125A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790936B1 (en) 1994-03-14 2004-09-14 The United States Of America As Represented By The Department Of Health And Human Services CAI resistance proteins and uses thereof
US5652223A (en) * 1994-03-14 1997-07-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services DNA encoding CAI resistance proteins and uses thereof
US6696558B2 (en) * 1998-09-09 2004-02-24 The Burnham Institute Bag proteins and nucleic acid molecules encoding them
CA2342027A1 (en) * 1998-09-09 2000-03-16 The Burnham Institute Novel bag proteins and nucleic acid molecules encoding them
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
EP1323733A1 (de) * 2001-12-28 2003-07-02 Arturo Leone BAG3-Nukleotid- und Proteinsequenzen zur Nutzung in Forschung, Diagnose und der Behandlung von Krankheiten, an denen Zelltod beteiligt ist
US7517697B2 (en) * 2003-02-05 2009-04-14 Applied Biosystems, Llc Compositions and methods for preserving RNA in biological samples
WO2007129598A1 (ja) 2006-05-02 2007-11-15 Teikyo University グルタチオン増加物質のスクリーニング方法
EP2676966A1 (de) * 2012-06-19 2013-12-25 Biouniversa S.r.l. BAG3 als biochemisches Serum und Gewebemarker

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359078A (en) * 1989-05-19 1994-10-25 The United States Of America As Represented By The Department Of Health And Human Services Signal transduction inhibitor compounds
US5652223A (en) * 1994-03-14 1997-07-29 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services DNA encoding CAI resistance proteins and uses thereof

Also Published As

Publication number Publication date
EP0750637B1 (de) 1998-12-30
EP0750637A1 (de) 1997-01-02
AU2126395A (en) 1995-10-03
ES2128048T3 (es) 1999-05-01
GR3029811T3 (en) 1999-06-30
DE69507017D1 (de) 1999-02-11
WO1995025125A1 (en) 1995-09-21
JPH09511236A (ja) 1997-11-11
DK0750637T3 (da) 1999-08-30
CA2185341A1 (en) 1995-09-21
US5652223A (en) 1997-07-29
AU684930B2 (en) 1998-01-08
US5981712A (en) 1999-11-09
DE69507017T2 (de) 1999-08-12

Similar Documents

Publication Publication Date Title
DE122010000023I2 (de) IL-1 Rezeptor Fusionsproteine verwendet als Antagoniste und Verfahren zu deren Verwendung und Herstellung.
DE69635482D1 (de) Säugetieren apoptosis inhibitorprotein genfamilie, primers, probes und verfahren zur nachweis
DE60137203D1 (de) Poröse ferro- oder ferrimagnetische glasteilchen für molekültrennung
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
ATE435280T1 (de) Methode zur isolierung von dna aus biologischen materialien
EP1687283A4 (de) Für die bestimmung von fk506 geeignetes verfahren und zusammensetzung
DE69939945D1 (de) Verfahren zur isolierung von stammzellen
WO2003048300A3 (en) Methods of identifying cellular target molecules
DE69824597D1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
DE69434614D1 (de) Cdn apoptosis modulierende proteine, sie kodierende dns und verfahren zu ihrer verwendung
ATE454468T1 (de) Nachweis der instabilität von mikrosatelliten und verwendung davon bei der tumordiagnose
ATE175212T1 (de) Cai-resistenzproteine kodierende dna, und ihre verwendung
ATE173544T1 (de) Parvovirusrezeptoren und verfahren zur ihrer verwendung
ATE319814T1 (de) Luciferase, fluoreszenzproteine, für luciferase und fluoreszenzproteine kodierend nukleinsaüre und ihre verwendung in der diagnose, hoch- durchsatz screeningsverfahren
ATE239274T1 (de) Proteom-analyse zum charakterisieren von auf- und abgeregelten proteinen in biologischen proben
DE69826493D1 (de) Ikk-alpha proteine, nukleinsäuren und verfahren
ATE310085T1 (de) Cyclin-e2 proteine und dafür kodierende gene
SI1465927T1 (sl) Protitelesa proti BAG3 za uporabo pri raziskavi, diagnostiki in terapiji bolezni, ki vključujejo celično smrt
DK1051491T3 (da) Equin Fc Epsilon receptor-alfa-kæde-nukleinsyremolekyler, korresponderende proteiner og anvendelse heraf
ATE166395T1 (de) Für c.difficile spezifische oligonukleotide
CA2273855A1 (en) Novel feline fc epsilon receptor alpha chain nucleic acid molecules, proteins and uses thereof
DE60108337D1 (de) Methode und testsatz zur detektion von schistosomiasis mittels polymerasekettenreaktion
DE60221550D1 (de) Methode zur bestimmung der zellzyklusposition
CA2331742A1 (en) Methods for quantitating low level modifications of nucleotide sequences
EP1241269A3 (de) Verfahren zum Nachweiss von REG-ähnliches Protein und dafür kodierende Nukleinäuren

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee